CANDEL THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
CANDEL THERAPEUTICS, INC. (CADL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $6.46 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2026-03-31 was $6.11, a 7.56% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2025-03-31 was $6.61, a 178.90% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2024-03-31 was $2.37, a 24.04% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2023-03-31 was $3.12, a 3.11% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2025 was $6.55, a 115.46% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2024 was $3.04, a 24.59% increase from fiscal 2023.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2023 was $2.44, a 25.38% decline from fiscal 2022.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2022 was $3.27, a 20.22% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.46 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $6.11 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $6.55 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $6.54 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $6.51 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $6.61 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $3.04 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $3.04 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $2.86 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $2.37 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $2.44 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $2.53 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $2.49 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $3.12 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $3.27 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $3.32 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $3.30 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $3.22 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $2.72 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $2.41 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $1.53 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |